Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
10,891 total articles
Astec Industries, Inc. announced first quarter 2026 financial results with a 20.3% increase in net sales reaching $396.3 million, driven primarily by a 70.6% rise in Materials Solutions net sales. Despite the sales growth, net income declined sharply to $1.3 million from $14.3 million the prior year, affected by timing and mix shifts in Infrastruct…
J & J Snack Foods Corp. reported its fiscal 2026 second quarter results with net sales decreasing by 3.2% year-over-year to $344.8 million primarily due to expected declines in the bakery segment. Despite lower sales, gross profit improved by 3.8% and gross margin expanded. Operating income decreased substantially due to non-recurring plant closure…
Advantage Solutions Inc. delivered a solid first quarter with revenues increasing 5.8% to $869.6 million and Adjusted EBITDA growing 16.4% to $67.7 million, driven primarily by strong performance in Experiential Services and improved profitability in Retailer Services. Despite a net loss widening to $71.8 million due to higher expenses and non-cash…
Relmada Therapeutics, a clinical-stage biotech firm focusing on oncology and CNS therapies, will report its first quarter 2026 financial results on May 12, 2026, and host a conference call to discuss recent business progress and financial performance.
Climb Global Solutions (NASDAQ: CLMB) has announced a new exclusive North American distribution partnership with Dashlane, expanding access to Dashlane's Omnix credential security platform to U.S. and Canadian resellers. This collaboration aims to enhance enterprise security by proactively protecting employee credentials and accelerating Dashlane's…
GDS Holdings Limited, a leading developer and operator of high-performance data centers in China, will report its unaudited first quarter 2026 financial results on May 20, 2026, prior to U.S. market open. The company will host an earnings conference call on the same day for investors and analysts, providing insights into its financial performance a…
Aquestive Therapeutics will report its financial results for the first quarter ending March 31, 2026, on May 13, followed by an investor call on May 14. The company highlighted ongoing development programs including its Anaphylm™ sublingual film and AQST-108 topical gel, advancing treatments for severe allergic reactions and dermatological conditio…
TG Therapeutics reported strong first quarter 2026 financial results with total global revenue of $205 million, highlighted by a 63% increase in U.S. net revenue for BRIUMVI, its treatment for relapsing multiple sclerosis. The company raised its full-year 2026 revenue guidance to approximately $925 million globally and increased its BRIUMVI U.S. ne…
Hyperion DeFi, Inc., a Nasdaq-listed decentralized finance company, announced the pricing of a public offering of nearly 2.78 million common shares at $3.60 per share, expected to raise approximately $10 million. The proceeds are to be used to enhance its treasury strategy by acquiring additional HYPE tokens and for general corporate purposes. The …
Eupraxia Pharmaceuticals announced the first release of EoEHSS sub scores data from its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for treating eosinophilic esophagitis (EoE). The data showed significant improvements in esophageal tissue inflammation and fibrosis at both 12 and 36 weeks, especially at the highest dose cohort. These findi…
The Brink's Company (NYSE: BCO) reported a robust first quarter financial performance for 2026, with 10% revenue growth including 4.5% organic growth and strong margins in high-growth segments like ATM managed services and digital retail. Operating cash flows increased, with free cash flow surpassing $500 million on a trailing-twelve-month basis fo…
Anavex Life Sciences Corp. has appointed former Senior VP of Clinical Development Terrie Kellmeyer, PhD, as Interim CEO after the resignation of Christopher Missling. Dr. Kellmeyer brings extensive experience in clinical development, regulatory affairs, and quality assurance and will focus on advancing Anavex's clinical programs, particularly its l…
Strata Critical Medical announced an 87.4% year-over-year revenue increase to $67.4 million in Q1 2026, driven by strong organic growth in its logistics segment and the addition of new clinical offerings following the Keystone acquisition. The company posted a net income of $2.4 million from continuing operations, improved gross margins, and strong…
Tempest Therapeutics announced clinical updates from its ongoing Phase 1 trials of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy. The updated data show a 100% complete response rate among 15 CAR-T-naïve efficacy evaluable patients treated in the REDEEM-1 and POEMS-1 trials for relapsed/refractory multiple myeloma and POEMS syndrome, respectiv…
Madrigal Pharmaceuticals announced first-quarter 2026 financial results demonstrating a 127% year-over-year increase in net sales of its key drug Rezdiffra, reaching $311.3 million. The company highlighted strong patient adoption, with over 42,250 patients on Rezdiffra, and expanded its pipeline through a global licensing agreement for a clinical-s…
Tonix Pharmaceuticals announced an agreement with a major group purchasing organization to provide commercial payer coverage for TONMYA® (cyclobenzaprine HCl sublingual tablets), a first-in-class FDA-approved non-opioid treatment for fibromyalgia in adults. The agreement grants access to around 35 million commercial lives in the U.S., representing …
U.S. Energy Corp. (NASDAQ: USEG) has been selected to participate in the inaugural Emerging Company Pavilion at the 31st Annual Sohn Investment Conference on May 12, 2026. This selection recognizes the company's growth trajectory and market potential, offering exposure to leading institutional investors and enhancing its profile in helium, carbon m…
KVH Industries announced its Q1 2026 results with revenues up 27% year-over-year to $32.3 million, driven primarily by a 30% increase in service revenue led by growth in low Earth orbit (LEO) satellite service sales from Starlink and OneWeb. The company reported a net income of $0.6 million, compared to a loss in the prior year period, and a substa…
Sprott Inc. reported a 9% increase in Assets Under Management (AUM) to $65.1 billion for Q1 2026, driven by market appreciation and net inflows, especially in precious metals and critical materials funds. Revenues and net income significantly increased compared to Q1 2025, supported by higher management fees, carried interest, and ETF expansion, in…
Geron Corporation announced an 8% increase in net revenue for its approved blood cancer drug RYTELO in Q1 2026 compared to Q4 2025, driven by higher demand and expanded ordering accounts. The company reaffirmed its 2026 revenue and expense guidance, highlighted progress in European commercial strategy and clinical trials, and strengthened its leade…
Kymera Therapeutics, a clinical-stage biotech company focused on targeted protein degradation therapies for immunological diseases, announced participation in two upcoming investor conferences in May 2026. The company will hold fireside chats at the Bank of America and RBC Capital Markets healthcare conferences, with live webcasts available on thei…
Energous Corporation, a Nasdaq-listed leader in over-the-air wireless power networks, announced its participation in a fireside chat at Planet MicroCap Las Vegas 2026. The event will feature key executives discussing the company’s strategy and growth, providing an opportunity for investor engagement and visibility in the microcap community.
BioCryst Pharmaceuticals announced its first quarter 2026 financial results highlighting an 11% year-over-year increase in net revenue for ORLADEYO to $148.3 million. The company also revealed a $70 million upfront licensing agreement with Neopharmed Gentili for the European commercial rights to navenibart, with potential milestone payments up to $…
EyePoint, Inc. announced its first quarter 2026 financial results highlighting ongoing Phase 3 clinical trials for its lead product candidate DURAVYU in wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company expects topline data for wet AMD trials starting mid-2026 and anticipates completing enrollment for DME …
Immunocore Holdings plc reported a 14% year-over-year increase in Q1 2026 net sales of its lead product, KIMMTRAK, reaching $106.7 million globally. Landmark five-year survival data presented at AACR 2026 demonstrated that KIMMTRAK doubles the likelihood of survival in metastatic uveal melanoma patients. The company is progressing multiple Phase 3 …
